Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jul 25;10(1):313.
doi: 10.1186/s13104-017-2633-6.

Emergence of fluoroquinolone resistance among drug resistant tuberculosis patients at a tertiary care facility in Karachi, Pakistan

Syed Mohammad Asad Zaidi  1 , Abdul Haseeb  2 , Shifa Salman Habib  3 , Amyn Malik  1 , Saira Khowaja  1 , Nausheen SaifUllah  2 , Nadeem Rizvi  2
Affiliations

Emergence of fluoroquinolone resistance among drug resistant tuberculosis patients at a tertiary care facility in Karachi, Pakistan

Syed Mohammad Asad Zaidi et al. BMC Res Notes. .

Abstract

Background: Pakistan is classified as one of the high multi-drug resistant tuberculosis (MDR-TB) burden countries. A poorly regulated private sector, over-prescription of antibiotics and self-medication has led to augmented rates of drug-resistance in the country. Pakistan's first national anti-tuberculosis drug resistance survey identified high prevalence of fluoroquinolone resistance among MDR-TB patients. Further institutional evidence of fluoroquinolone drug-resistance can support re-evaluation of treatment regimens as well as invigorate efforts to control antibiotic resistance in the country.

Findings: In this study, data for drug-susceptibility testing (DST) was retrospectively analyzed for a total of 133 patients receiving MDR-TB treatment at the Chest Department of Jinnah Postgraduate Medical Center, Karachi, Pakistan. Frequency analyses for resistance patterns was carried out and association of fluoroquinolone (ofloxacin) resistance with demographics and past TB treatment category were assessed. Within first-line drugs, resistance to isoniazid was detected in 97.7% of cases, followed by rifampicin (96.9%), pyrazinamide (86.4%), ethambutol (69.2%) and streptomycin (64.6%). Within second-line drugs, ofloxacin resistance was detected in 34.6% of cases. Resistance to ethionamide and amikacin was 2.3% and 1.6%, respectively. Combined resistance of oflaxacin and isoniazid was detected in 33.9% of cases. Age, gender and past TB treatment category were not significantly associated with resistance to ofloxacin.

Conclusion: Fluoroquinolone resistance was observed in an alarmingly high proportion of MDR-TB cases. Our results suggest caution in their use for empirical management of MDR-TB cases and recommended treatment regimens for MDR-TB may require re-evaluation. Greater engagement of private providers and stringent pharmacy regulations are urgently required.

Keywords: Fluoroquinolone resistance; Multi-drug resistant tuberculosis; Pakistan.

PubMed Disclaimer

References

    1. Organization WH. Global tuberculosis control: surveillance, planning, financing: World Health Organization; 2007.
    1. Organization WH . The Burden of Disease Caused by TB. Geneva: World Health Organization; 2013.
    1. Hasan R, Jabeen K, Ali A, Rafiq Y, Laiq R, Malik B, et al. Extensively drug-resistant tuberculosis, Pakistan. Emerg Infect Dis. 2010;16(9):1473–1475. doi: 10.3201/eid1609.100280. - DOI - PMC - PubMed
    1. Jabeen K, Shakoor S, Chishti S, Ayaz A, Hasan R. Fluoroquinolone-resistant Mycobacterium tuberculosis, Pakistan, 2005–2009. Emerg Infect Dis. 2011;17(3):566. doi: 10.3201/eid1703.100957. - DOI - PMC - PubMed
    1. Tahseen S, Qadeer E, Khanzada FM, Rizvi AH, Dean A, Van Deun A, Zignol M. Use of Xpert® MTB/RIF assay in the first national anti-tuberculosis drug resistance survey in Pakistan. Int J Tuberc Lung Dis. 2016;20(4):448–455. doi: 10.5588/ijtld.15.0645. - DOI - PubMed

LinkOut - more resources